

Special Issue

mRNA-Based Protein Replacement Therapy

Message from the Guest Editor

The way by which the genetic information bearing by mRNAs is translated in ribosomes contributes to molecular mechanisms that support the cellular decisions for the entire lifetime of the organisms. Nowadays research efforts are focusing on further exploitation of mRNA-based therapeutics to achieve major healthcare benefits by developing cancer vaccines, tumor immunotherapy, protein replacement, and gene editing protocols. In this Special Issue, we welcome articles dealing with all aspects of mRNA-based protein replacement therapy to combat illnesses. Additionally, protocols and approaches with supporting data that improve physicochemical properties, cellular behavior, function, and translation rate, as well as providing evidence of biodistribution, pharmacokinetics, and clinical effectiveness of mRNA-based replacement therapy platforms are also invited for submission and publication. Moreover, we welcome work dealing with the development and application of safe and effective in vivo delivery systems for mRNA therapeutics, including those with targeting propensity of particular cells or organs in the body.

Guest Editor

Prof. Dr. Ioannis S. Vizirianakis

Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece

Deadline for manuscript submissions

closed (30 November 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/124563

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).